Welcome to the Miller Lab at the Medical College of Wisconsin Cancer Center. Our lab is focused on understanding the causes of drug resistance in breast cancer and the discovery of new treatment strategies.
Epithelial-mesenchymal transition is associated with altered immune composition and cytotoxic function in triple-negative breast cancer.
Hanxu Lu, Meisam Bagheri, Fred W Kolling, Lucas A Salas, Xiaofeng Wang, Todd W Miller, Diwakar R Pattabiraman, Brock Christensen.
Breast Cancer Res. 2026 Jul 16;28(1):132. doi: 10.1186/s13058-026-02309-5.
Pharmacological chromatin remodeling enhances response to estrogen therapy in ER<sup>+</sup> breast cancer.
Anneka L Johnson Thomas, Barbara Karakyriakou, Patricia C Muskus, Alyssa M Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A Birmingham, Malone K Friedman, Abigail E Goen, Huijuan Yang, Owen M Wilkins, Fred W Kolling, Eugene Demidenko, Julie M Jorns, Brock C Christensen, Todd W Miller.
Mol Oncol. 2026 Jul 17:10.1002/1878-0261.70307. doi: 10.1002/1878-0261.70307. Online ahead of print.
Metabolic Response to CDK4/6 Inhibition in ER+ Breast Cancer Creates a Therapeutic Vulnerability in Drug-Tolerant Persister Cells.
Huijuan Yang, Steven Tau, Andrew D McCray, Alyssa M Roberts, Jonathan D Marotti, Kristen Muller, Yuzhou Huang, Md Al Mamun, Kazuhiro Aoki, Eugene Demidenko, Todd W Miller.
FASEB J. 2026 Apr 15;40(7):e71746. doi: 10.1096/fj.202502515RR.